RxDoctor Payments Data

Ian Chua

Family Medicine · Orlando, FLNPI 1912135435

Payments from drug & device makers

$5,015in general payments, 2019–2025

Across 52 payments — averaging $96.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Gilead$1K
  • La Jolla Pharmaceutical Company$545
  • AstraZeneca$374
  • GSK$258
  • Pfizer$217
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$76015%
  • Food & beverage$4,25585%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson13$1,235
Gilead6$1,194
La Jolla Pharmaceutical Company5$545
AstraZeneca(2 entities)4$374
GSK3$258
Pfizer7$217
Mylan Specialty L.p.4$200
Merck2$160
Ferring Pharmaceuticals Inc.1$145
Novartis1$123
Tetraphase Pharmaceuticals, Inc.1$115
Philips North America LLC2$115
Novo Nordisk1$114
Fisher Scientific Company L.L.C.1$113
AbbVie1$109

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,015 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$126,722
Medicare patients
480
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$17,368
XareltoRivaroxaban15$7,250
Ondansetron OdtOndansetron303$3,079
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen179$1,320
Methocarbamol193$861
Pantoprazole Sodium136$591
Oxycodone Hcl86$489
Cefadroxil20$398
Celecoxib24$341
Gabapentin37$337
Dexamethasone47$244
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$238
Doxycycline Monohydrate11$183
Doxycycline Hyclate24$179
Cefdinir12$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$217$17,36831 claims
Johnson & JohnsonXarelto$1,235$7,25015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →